Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease
- Conditions
- Peripheral Arterial Disease
- Interventions
- Procedure: Long lesion stentingProcedure: Short spot stenting
- Registration Number
- NCT03227822
- Lead Sponsor
- Catharina Ziekenhuis Eindhoven
- Brief Summary
Since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (\> 1) short (focal; \> 1 and \< 5 cm) SFA lesions can be improved by spot stenting as compared to the use of one long stent. This study proposes to evaluate the endovascular treatment for patients with SFA lesions by comparing two strategies for patients with extensive occlusive SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 3
- PAOD (ABI <0.90 and/or a decline of >0.15 after exercise test), Rutherford category 2, 3 or 4
- Multiple (>1) short (focal; >1 and < 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery
- Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines
- Unilateral occlusive disease
- Age ≥ 18
- Patients with PAOD Rutherford category 5 and 6
- Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat
- Bilateral lesions with treatment indication
- Contra-indication for anticoagulant therapy
- Renal insufficiency (MDRD < 50 ml/min)
- Life expectancy < 6 months
- Known contrast allergy
- Pregnancy
- Unable to complete a questionnaire in the home language
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Long lesion stenting Long lesion stenting Long lesion stenting Short spot stenting Short spot stenting Short spot stenting
- Primary Outcome Measures
Name Time Method absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention 1 year
- Secondary Outcome Measures
Name Time Method